Regulation & law · 06/11/2018Updated: 10/17/2026 · 1 min read
NHLBI Considers Exclusive Patent License for Insulin Resistance and NASH Treatment
Summary
The National Heart, Lung and Blood Institute is considering granting Ovensa, Inc. an exclusive patent license to commercialize treatments for insulin resistance and non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).